IR News 2025

Kyoto, Japan, January 10, 2025 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced that the National Center of Neurology and Psychiatry　(NCNP, Kodaira City; President, Kazuyuki Nakagome)  has published the results of an investigator-initiated clinical trial (First in human trial) of NS-089/NCNP-02, which is being developed by Nippon Shinyaku for the treatment of Duchenne muscular dystrophy (DMD), in the journal Cell Reports Medicine. Please check the press release from NCNP for summary of the paper. https://www.ncnp.go.jp/topics/detail.php?@uid=GHiBUYrxzfWih41S 

Additionally, the paper is available for free viewing.

NS-089/NCNP-02 is a nucleic acid drug co-discovered by Nippon Shinyaku and NCNP, and is expected to be a therapeutic drug for DMD patients with dystrophin gene mutations amenable to exon 44 skipping.

A global Phase II study of NS-089/NCNP-02 is being conducted by Nippon Shinyaku and NS Pharma, Inc. (Headquarters: New Jersey, USA; President: Yukiteru Sugiyama).

Nippon Shinyaku has been working actively with a sense of mission to develop agents for the treatment of intractable and rare diseases, with a view to launching products for DMD patients as soon as possible.

Contact

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.